Liver cancer a global public health concern and well known for poor prognosis. The association between low total cholesterol level and liver cancer has been reported. However, the association between low low-density lipoprotein (LDL) cholesterol levels and liver cancer is still unclear. The aim of this study was to examine the relationship between LDL cholesterol level and liver cancer mortality. A total of 16,217 persons (5,551 men and 10,666 women) aged 40-79 years in 1993 were followed until 2008. LDL cholesterol levels were divided into four categories (< 80 mg/dl, 80-99 mg/dl, 100-119 mg/dl, and ≥ 120 mg/dl). Hazard ratio of LDL cholesterol level for liver cancer mortality was calculated using a multivariable Cox proportional hazards model. Covariates were age, sex, alanine transaminase, body mass index, alcohol intake and smoking status, all of which were correlated with LDL cholesterol levels. There were 51 deaths (32 men and 19 women) from liver cancer. Multivariable hazard ratios of liver cancer deaths for LDL cholesterol levels of < 80 mg/dl was 4.33 (95% confident interval [CI]: 1.94, 9.68), for LDL cholesterol levels of 80-99 mg/dl was 1.03 (95% CI: 0.42, 2.53), and for LDL cholesterol levels of ≥ 120 mg/dl was 0.43 (95% CI: 0.20, 0.92) compared with LDL cholesterol levels of 100-199 mg/dl (p for trend < 0.01). Therefore, low LDL cholesterol levels are associated with elevated risk of liver cancer mortality. Low LDL cholesterol may be a predictive marker for death due to liver cancer.
Introduction
In 2008, an estimated 695,000 people died of liver cancer world-wide (Lee et al. 2010) . Liver cancer is a major global public health concern and well known for a poor prognosis. Moreover, early liver cancer is often asymptomatic. Screening for hepatitis B virus antigen and hepatitis C virus antibodies is performed in Japan, and some people are examined by ultrasonography in specific communities (Ando et al. 2006) .
Elevated total cholesterol (TC) level is a causal risk for coronary heart diseases (Weinehall et al. 1998; Okamura et al. 2003) . In contrast, low TC levels have been reported to be a predictive marker for total mortality, including total cancer mortality (Levy 1982) . Previous studies showed that low TC levels were not a cause of total cancers (Hiatt and Fireman 1986; Wald et al. 1989 ), but preclinical total cancers had lower cholesterol levels (Hiatt and Fireman 1986; Wald et al. 1989; Okamura et al. 2003) , including liver cancer. Therefore, the hypothesis was that persons with low low-density lipoprotein (LDL) cholesterol levels may have already been affected by liver cancer. However, the relationship between low LDL cholesterol level and liver cancer remains unclear despite the association between low TC levels and liver cancer (Okamura et al. 2007) .
In Japan, the Specific Health Checkup and Specific Counseling started in 2008, for citizens aged 40-74 years. The checkup items which are associated with lipids include LDL cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride. Therefore, LDL cholesterol level measurement is included in the checkup to identify persons with a high level of LDL cholesterol, and health counseling is conducted for persons with a high level of LDL cholesterol. In contrast, no consultation is done for persons with a low level of LDL cholesterol. A checkup of liver cancer for persons with a low LDL cholesterol level would be recommended if low LDL cholesterol level is associated with liver cancer. Because TC is not included in the Specific Health Checkup, it is important to determine the association between LDL cholesterol level and liver cancer mortality.
The aim of the present study was to examine the relationship between LDL cholesterol level and liver cancer mortality.
Methods

Study population
The Ibaraki prefectural government initiated a communitybased large cohort study, known as the Ibaraki Prefectural health study, in 1993 to obtain information on health status for the purpose of health education and policy making. Our study was a cohort design and we used data obtained from the Ibaraki Prefecture study. The cohort included 97,042 individuals (33,130 men and 63,912 women) aged 40 to 79 years living in Ibaraki Prefecture who completed an annual health checkup conducted by the Ibaraki Health Service Association in 1993.
To calculate LDL cholesterol, we used the Friedewald formula, which requires fasting triglyceride levels and fasting triglyceride <400 mg/dl (Friedewald et al. 1972); therefore, 80,610 persons (27,443 men and 53,167 women) were excluded from the analysis because of non-fasting serum and 170 persons (121 men and 49 women) had a triglyceride level of 400 mg/dl or more. We also excluded 45 persons (15 men and 30 women) because of incomplete data. Thus, a total of 16,217 persons (5,551 men and 10,666 women) were followed until the end of 2008 (Fig. 1) . The mean follow-up period was 14.1 years. Informed consent was obtained from community representatives to conduct an epidemiological study based on guidelines of the Council for International Organizations of Medical Science. The protocol of this cohort study was approved by the Ibaraki Epidemiology Study Union Ethics Review Committee.
Baseline examinations
At baseline, blood samples were obtained from seated participants and placed into two polyethylene terephthalate tubes: one tube with an accelerator, and the other with sodium fluoride and ethylenediaminetetraacetic acid. Serum TC and triglyceride were measured with an enzymatic method using an RX-30 device (Nihon Denshi, Tokyo, Japan). High-density lipoprotein (HDL) cholesterol level was measured with a phosphotungstic acid magnesium method using an MTP-32 device (Corona Electric, Hitachinaka, Japan). These mea- (Atlanta, GA) and has met all the criteria for both precision and accuracy of lipid measurements (Nakamura et al. 2003) . LDL cholesterol was calculated using the Friedewald formula as follows: LDL cholesterol (mg/dl) = Total cholesterol (mg/dl) − HDL cholesterol (mg/dl) −0.2*triglycerides (mg/dl) (Friedewald et al. 1972) . Aspartate transaminase (AST) and alanine transaminase (ALT) were measured with Japan Society of Clinical Chemistry (JSCC) transferable methods using an RX-30 device (Nihon Denshi, Tokyo, Japan).
Height in stocking feet and weight in light clothing were measured, and body mass index (BMI) was calculated as weight (kg) divided by the square of height (m 2 ). An interview was conducted to ascertain alcohol intake (never, sometimes, < 66 g/day, or ≥ 66 g/day), smoking status (never smoked, former smoker, or current smoker), and for current smokers, the number of cigarettes smoked per day. Heavy drinkers were defined as persons who drink over 3 go/day (66 g/day of ethanol) (Japan Health Promotion & Fitness Foundation, 2000) .
Follow-up surveillance
In order to ascertain deaths in the cohort, investigators conducted a systematic review of death certificates. Data from health checkups and date of death or moving were obtained from local governments. All deaths that occurred in the cohort were ascertained, except for subjects who died after they had moved from their original community, in which case those subjects were withdrawn from the study. Data on death are centralized at the Ministry of Health and Welfare, where the underlying causes of death are coded for the National Vital Statistics according to the International Classification of Diseases (ICD), 9th (1993-1994), and 10th (1995-2008) revisions. The underlying causes of death of this cohort were obtained from the Ministry of Health and Welfare. Record matching between the residence certificates and the underlying causes of death was done using residential area, gender, birthday, and death date. Liver cancer deaths were identified as code 155 in the ICD-9 and as code C22 in the ICD-10. Liver cirrhosis deaths were identified as code 11301 in the ICD-9 and as code K74.3-6 in the ICD-10.
Statistical analysis
Person-years of follow-up were calculated from the date of the baseline survey in 1993 to the date of death due to liver cancer or other causes, exit from the community, or the end of 2008, whichever occurred first. Statistical analysis was based on mortality rates from liver cancer stratified by LDL cholesterol levels (< 80 mg/dl, 80-99 mg/dl, 100-119 mg/dl, and ≥ 120 mg/dl). A LDL cholesterol level < 120 mg/dl is defined as the desirable level by Japan Atherosclerosis Society (Teramoto et al. 2007) . In this study, LDL cholesterol level 100-119 mg/dl was used as a reference. The p values for differences in baseline characteristics stratified by LDL cholesterol levels were calculated by an analysis of variance. Risk ratios of liver cancer mortality (excluding cases diagnosed in the first five years), and liver cirrhosis mortality were calculated using a multivariable Cox proportional hazards model after adjustment for age, sex, and potential confounding factors. These factors included alanine transaminase (ALT), BMI, alcohol intake (never, sometimes, < 66 g/day, and ≥ 66 g/day), and smoking status (never smoked, former smoker, current smoker < 20 cigarettes/day, and current smoker ≥ 20 cigarettes/day). A p-value < 0.05 was regarded as statistically significant. P for trend was calculated using categorical LDL cholesterol variables. Population attributable risk was calculated using the following formula:
{pd i = population of cases falling into ith exposure level; RR i = relative risk comparing ith exposure level with unexpected group (i = 0)} (Rockhill et al. 1998 ). All statistical analyses were conducted using SAS, version 9.1 (SAS Institute, Inc., Cary, USA).
Results
The baseline characteristics and mortality rates of persons who had fasting or non-fasting serum are shown in Table 1 . Fasting persons tended to be younger and had high ALT levels, high gamma-glutamyltransferase (γ-GT) levels, and low triglyceride levels. For all causes, the mortality rate of fasting persons was lower than that of non-fasting persons.
The baseline characteristics of the study subjects are shown in Table 2 . Persons who had lower levels of LDL cholesterol tended to be younger and had high aspartate transaminase (AST) levels, high ALT levels, and high γ-GT levels.
During follow-up through 2008, there were 32 liver cancer deaths among the 5,551 men (76,624.5 person years), and 19 liver cancer deaths among the 10,666 women (151,814.3 person years). There were 954 persons who moved away, and it was not clear how many people died after they moved. The sex and age-specific total cholesterol levels of the study subjects were higher than those of nonfasting and fasting subjects (Table 3) .
In an analysis performed with gender combined data, there were no interactions between gender and the relationship of LDL cholesterol and liver cancer mortality (P = 0.892). Table 4 shows multivariable hazard ratio (HR) for liver cancer mortalities adjusted for age, sex and covariates according to LDL cholesterol levels. The mortality for liver cancer deaths was the highest in the lowest LDL cholesterol category. HR adjusted for age and sex was 5.02 (95% confident interval [CI]: 2.30, 10.92). HR adjusted for covariates was 4.33 (95% CI: 1.94, 9.68) and p for trend was < 0.01. The population attributable risk of low LDL cholesterol (< 80 and 80-99 mg/dl) for liver cancer mortality among subjects with normal LDL cholesterol (< 120 mg/dl) was 8.7%. Table 5 shows HR of liver cancer mortality (excluding cases diagnosed in the first five years) stratified by LDL cholesterol levels. The HRs of low LDL cholesterol were relatively small compared with those including deaths in the first five years. Table 6 shows HR of liver cancer mortality stratified by LDL cholesterol levels (cardiovascular disease excluded). The HRs showed similar finding to the HRs of Table 4 .
Kaplan-Meir survival curves for LDL groupings are shown in Fig. 2 . The survival rates were 98.3% for LDL cholesterol < 80 mg/dl; 99.5% for 80-99 mg/dl; 99.6% for 100-119 mg/dl; and 99.8% for ≥ 120 mg/dl. Table 7 shows HR of liver cirrhosis mortality stratified by LDL cholesterol levels. The mortality for liver cirrhosis deaths was the highest in the lowest LDL cholesterol category. HR adjusted for age and sex was 11.10 (95% CI: 2.73, 45.17). HR adjusted for covariates was 7.01 (95% CI: 1.59, 30.89) and p for trend was < 0.01. Table 8 shows HR of liver cirrhosis and liver cancer mortality stratified by LDL cholesterol levels. The mortality for liver cirrhosis and liver cancer deaths was the highest in the lowest LDL cholesterol category. HR adjusted for † Cox proportional hazards model adjusted by age, sex, ALT, body mass index, alcohol intake (never, sometimes, < 66 g/day, or ≥ 66 g/day), and smoking status (never smoked, former smoker, or current smoker). † Cox proportional hazards model adjusted by age, sex, ALT, body mass index, alcohol intake (never, sometimes, < 66 g/day, or ≥ 66 g/day), and smoking status (never smoked, former smoker, or current smoker).
age and sex was 6.06 (95% CI: 3.08, 11.92). HR adjusted for covariates was 4.83 (95% CI: 2.40, 9.72) and p for trend was < 0.01.
Discussion
To the best of our knowledge, this is the first study to demonstrate an association between low LDL cholesterol level and liver cancer mortality. Moreover, no statistically significant differences were found for mortality related to liver cancer (excluding cases diagnosed in the first five years). The findings of this study indicate that low LDL cholesterol may be a predictive marker for death due to liver cancer.
A previous study (Rose et al. 1974) reported that men with colon cancer have lower cholesterol levels than control subjects. Several follow-up studies (Kark et al. 1980; Williams et al. 1981; Levy 1982) confirmed the association between total cancer and low total cholesterol levels. The In this analysis, we excluded subjects who died from cardiovascular disease. * Cox proportional hazards model adjusted by age and sex. † Cox proportional hazards model adjusted by age, sex, ALT, alcohol intake (never, sometimes, <66g/day, or ≥66g/ day), and smoking status (never smoked, former smoker, or current smoker). Framingham study (Williams et al. 1981 ) reported that low total cholesterol level was associated with incidence of colon cancer and with other cancer sites among 5,209 male subjects followed for 24 years. In this study, the mortality for liver cancer deaths was the highest in both men and women with the lowest TC levels. So, preclinical cancer in some ways may lower serum cholesterol levels (Grundy et al. 2004) . In 1990, TC and LDL cholesterol levels were associated with total cancer mortality in men (Cowan et al. 1990 ). Several follow-up studies (Benn et al. 2011; Nago et al. 2011) confirmed the association between total cancer and low LDL cholesterol levels. In the present study, the mortality for liver cancer deaths was the highest in the lowest LDL cholesterol levels for both men and women. It has been suggested that lower cholesterol levels might increase the risk of cancer (Levy 1982) . However, most of these studies were restricted only to men, and the sample sizes were small. Our findings suggest that preclinical cancer could have some effect which causes a reduction in cholesterol levels. In a previous study (Grundy et al. 2004) , 24 men and 7 women who died of liver cancer had LDL cholesterol levels < 100 mg/dl. Preclinical cancer may have influenced cholesterol level within two years of their diagnosis of cancer. Some persons may have low LDL cholesterol levels because of undiagnosed liver cancer.
The possible mechanism of the association between total cholesterol and liver cancer has been previously reported (Forns et al. 2002; Ooi et al. 2005; Iso et al. 2009 ). Because the liver is the only organ that produces cholesterol and liver cancer is usually accompanied by liver cirrhosis, liver cancer may lower serum cholesterol levels (Iso et al. 2009 ). When hepatic dysfunction occurs because of liver cancer and chronic liver diseases, esterification and evacuation of cholesterol are blocked, which causes changes of plasma cholesterol levels (Ooi et al. 2005 ). Furthermore, the cholesterol level among patients with hepatitis B and hepatitis C was an independent predictor of fibrosis (Forns et al. 2002; Tanaka et al. 2004 ). The pathological mechanism might be chronic necroinflammatory hepatic change, which in turn acts as a promoter in the multistep process of carcinogenesis. Hepatitis B virus DNA integrates in chromosomal DNA and is believed to contribute to the genesis of hepatocellular carcinoma (Tanaka et al. 2004 ). Thus, low cholesterol was a marker for liver fibrosis, which is a † Cox proportional hazards model adjusted by age, sex, ALT, body mass index, alcohol intake (never, sometimes, < 66 g/day, or ≥ 66 g/day), and smoking status (never smoked, former smoker, or current smoker). † Cox proportional hazards model adjusted by age, sex, ALT, body mass index, alcohol intake (never, sometimes, < 66 g/day, or ≥ 66 g/day), and smoking status (never smoked, former smoker, or current smoker). major finding in liver cirrhosis. In the present study, low LDL cholesterol level was also associated with liver cirrhosis mortality, which finding underlined those mechanisms. This suggests that low cholesterol per se might not be a cause for liver cancer.
Compared with previous cohort studies, the strengths of this study were a large sample size and a long follow-up period (Kark et al. 1980; Cowan et al. 1990 ). In addition, all blood samples were measured using the same device, reagents, and quality control program.
The present study has several limitations. First, we did not determine whether subjects had previous viral hepatitis or previous alcohol hepatitis, although alcohol intake was taken into account using multivariable Cox proportional hazards model. Second, the change in the ICD coding from version 9 to version 10 during the follow-up period may have been a confounding factor in the diagnosis of the cause of death. However, ICD coding was done by specialists in the Ministry of Health and Welfare, not by researchers, and mortality from cancer is known to be accurately reported on death certificates in Japan (Hasuo et al. 1989) . Third, the subjects of this study were participants in a health checkup for community residents with an approximately 40% response rate, so a "healthy" participant effect could have influenced our results. In addition, the subjects of the present study had higher total cholesterol compared with non-fasting and fasting subjects, so selection bias might have occurred. Further study is warranted to clarify the generalizability and effect of healthy participants.
In conclusion, an association between low LDL cholesterol level and liver cancer mortality was found. Therefore, low LDL cholesterol may be a predictive marker for death due to liver cancer.
